Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.
PR Newswire, 810 Seventh Avenue, New York, NY 10019 - Tuesday, 1 October 1996
Conservative estimates of those individuals who have genital herpetic infections are 30-40 million in the U.S. Oral herpetic infections are of a greater frequency. In newborns or in immunosuppressed patients (e.g. AIDS) it can lead to serious illness and death.
Vaccination against Herpes Simplex Virus has the potential to prevent or treat herpes simplex infection. Unlike most other viruses, once infected, a herpes virus remains in hiding within an individual and is reactivated often by stress inducing factors. For some individuals, these painful recurrences may occur as often as monthly. Although there are antiviral drugs to prevent serious disease and lessen the symptoms, there is currently no way to effectively prevent initial infection or eliminate the virus from an infected person or prevent recurrences.
The agreement will make use of CEL-SCI's new heteroconjugate technology which combines T-cell binding ligands with small, disease associated, peptide antigens. This technology is presently also undergoing testing with a view to the development of AIDS, malaria and tuberculosis vaccines.
The heteroconjugate technology is intended to selectively stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections and cancer, when it cannot do so on its own. Administered like vaccine, heteroconjugates may provide an exciting new class of products to treat and prevent these diseases.
Scientists at Northeastern Ohio Universities College of Medicine have been working on herpes virus methods of treatment and detection for over fifteen years.
CEL-SCI Corporation is a pioneer in the field of natural immunotherapy. It is developing Multikine(TM) for the treatment of cancers and other immunodeficiency diseases. In addition, it is developing the HGP-30 HIV vaccine/treatment and a tuberculosis vaccine/treatment.
FEDERAL FILINGS CONTACTS: (202) 393-7856 FOR EDITORIAL, (800) 487-6162 FOR DOCUMENT SALES, (202) 628-8990 FOR NEWSWIRE SALES, & (888) FED-FILE FOR TECHNICAL SUPPORT
Copyright (c) 1996/PR NewsWire. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, PR Newswire, 810 Seventh Avenue, New York, NY 10019.
961002
PR961002
Copyright © 1996 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .